ANP32B Antibody
Description
Introduction to ANP32B Antibody
The ANP32B antibody is a specialized immunological tool targeting acidic nuclear phosphoprotein 32 family member B (ANP32B), a conserved regulatory protein involved in cell differentiation, apoptosis, and proliferation . This antibody enables researchers to study ANP32B's roles in physiological and pathological processes, including cancer progression, immune regulation, and viral infections. ANP32B antibodies are critical for techniques such as Western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF/ICC) .
Role in Immune Regulation
ANP32B antibodies have been instrumental in uncovering the protein's immunomodulatory functions. Studies using Anp32b knockout (KO) mice revealed:
-
Enhanced autoimmune responses in experimental autoimmune encephalomyelitis (EAE), with increased Th17 cell activity and proinflammatory cytokine production (e.g., IL-17A, TNF-α) .
-
Hyperactivation of T lymphocyte pathways and altered CD4+/CD8+ T-cell ratios, linking ANP32B deficiency to autoimmune dysregulation .
Oncogenic Functions in Cancer
ANP32B antibodies validate its overexpression in malignancies and mechanistic roles:
-
Breast Cancer: ANP32B promotes tumor progression by regulating AKT phosphorylation. Silencing ANP32B reduces cell proliferation and induces G1 arrest .
-
Chronic Myeloid Leukemia (CML): ANP32B represses p53 activity, sustaining leukemic stem cell survival. Clinical samples show elevated ANP32B levels in CML bone marrow .
-
Hepatocellular Carcinoma (HCC): ANP32B knockdown reduces apoptosis by modulating Bad phosphorylation and Bak/Bax expression .
Apoptosis Regulation in Hepatocellular Carcinoma
Key findings using ANP32B-targeted siRNA and antibodies include:
Clinical Relevance and Therapeutic Potential
-
Diagnostic Utility: ANP32B antibodies detect overexpression in breast cancer and CML, correlating with histopathological severity .
-
Therapeutic Targets: ANP32B inhibition reduces viral replication (e.g., influenza, henipavirus) and sensitizes cancer cells to apoptosis .
-
Autoimmune Disorders: Dysregulated ANP32B expression may contribute to Th17-driven pathologies, suggesting immunotherapeutic applications .
Product Specs
Target Background
- Based on the cellular functions of characterized ProTalpha targets and the evolution of the composition of diverse ProTalpha complexes under conditions of reduced proliferation activity or induced apoptosis, it is hypothesized that ProTalpha interactions may be linked to proliferation activity and cell survival control. PMID: 29106904
- ANP32B modulates Bad phosphorylation, as well as Bak and Bax expression, resulting in the regulation of apoptosis in hepatocellular carcinoma (HCC). These findings suggest the potential of ANP32B as a therapeutic target for HCC. PMID: 28486557
- A caspase-3-resistant uncleavable form of acidic leucine-rich nuclear phosphoprotein 32B enhances leukemic cell apoptosis. PMID: 25483709
- ANP32B is a nuclear target of henipavirus M proteins. PMID: 24823948
- This is the first demonstration that ANP32B expression was down-regulated during differentiation induction of leukemic cells by all-trans retinoic acid. PMID: 22705300
- The interaction of ANP32B with the core histones H3-H4 occurs on its concave side, and both the acidic and hydrophobic residues that compose the concave surface are critical for histone binding. PMID: 20538007
- ANP32B is a direct substrate of caspase-3. It is cleaved at the sequence of Ala-Glu-Val-Asp, after Asp-163. The reduced expression of endogenous ANP32B by specific siRNA enhances caspase-3 activation and apoptosis induction by NSC606985 and etoposide. PMID: 20015864
- Regulatory roles of oncoprotein ProT and tumor suppressor PHAP in apoptosis. PMID: 12522243
- Recruitment of ANP32B onto the promoter region requires KLF5 and results in promoter region-specific histone incorporation and inhibition of histone acetylation by ANP32B. PMID: 18039846
- The CK2 alpha' phosphorylates APRIL and therefore is responsible for the regulation of the nucleocytoplasmic translocation of CD83 mRNA. PMID: 19130553
